Constellation Pharma Adds Onto Series B Round
Constellation Pharmaceuticals Inc., a Cambridge, Mass.-based developer of drugs that target selective regulators of epigenetic function, has raised $4.8 million in additional Series B funding led by S.R. One Ltd. The round is now closed at $22 million, including a $17.2 million first close announced last summer. Other backers include Altitude Life Science Ventures, Third Rock Ventures, The Column Group and Venrock. The company has raised a total of $54 million.
2 June 2010•3 mins read
